Charles River Laboratories International, Inc. (NYSE:CRL) Position Decreased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 36.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 31,305 shares of the medical research company’s stock after selling 17,725 shares during the period. Assenagon Asset Management S.A.’s holdings in Charles River Laboratories International were worth $5,779,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in CRL. American Century Companies Inc. boosted its position in shares of Charles River Laboratories International by 4.6% during the 2nd quarter. American Century Companies Inc. now owns 6,556 shares of the medical research company’s stock valued at $1,354,000 after purchasing an additional 291 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Charles River Laboratories International by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 561,075 shares of the medical research company’s stock worth $115,912,000 after purchasing an additional 93,682 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of Charles River Laboratories International by 74.5% in the second quarter. Mercer Global Advisors Inc. ADV now owns 4,031 shares of the medical research company’s stock worth $833,000 after purchasing an additional 1,721 shares in the last quarter. Amalgamated Bank lifted its position in shares of Charles River Laboratories International by 21.7% in the second quarter. Amalgamated Bank now owns 13,036 shares of the medical research company’s stock worth $2,693,000 after purchasing an additional 2,323 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Charles River Laboratories International in the second quarter worth approximately $124,000. Institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Trading Down 1.2 %

Shares of Charles River Laboratories International stock opened at $163.77 on Tuesday. The company’s fifty day simple moving average is $189.50 and its 200-day simple moving average is $198.14. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 1 year low of $160.85 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the company posted $2.72 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price objective for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective on the stock. Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. William Blair reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research report on Tuesday, January 14th. Finally, TD Cowen raised their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $209.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).